Targeting the DNA Damage Response for Anti-Cancer Therapy

Over the past decade a complex role for DNA damage response (DDR) in tumorigenesis has emerged. A proficient DDR has been shown to be a primary cause for cellular resistance to the very many DNA damaging drugs, and IR, that are widely used as standard-of-care across multiple cancer types. It has als...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Άλλοι συγγραφείς: Pollard, John (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt), Curtin, Nicola (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Cham : Springer International Publishing : Imprint: Humana, 2018.
Έκδοση:1st ed. 2018.
Σειρά:Cancer Drug Discovery and Development,
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
Πίνακας περιεχομένων:
  • 1. Targeting DNA repair in anti-cancer treatments
  • 2. The DNA damage response: roles in cancer etiology and treatment
  • 3. Control of DNA Replication by ATR
  • 4. Targeting ATR for cancer therapy: Profile & expectations for ATR inhibitors
  • 5. Targeting ATR for cancer therapy: ATR-targeted drug candidates
  • 6. ATM: its recruitment, activation, signalling and contribution to tumour suppression
  • 7. Pre-clinical profile and expectations for pharmacological ATM inhibition
  • 8. Targeting ATM for cancer therapy: Prospects for drugging ATM
  • 9. Targeting Chk1 for cancer therapy: rationale, progress and prospects
  • 10. Preclinical profiles and contexts for CHK1 and CHK2 inhibitors
  • 11. Clinical development of CHK1 inhibitors
  • 12. Established and emerging roles of the DNA-dependent protein kinase catalytic subunit (DNA-PKcs)
  • 13. Targeting DNA-PK as a therapeutic approach in oncology
  • 14. Dbait: a new concept of DNA repair pathways inhibitor from bench to bedside
  • 15. Alternative Non Homologous End-joining: Mechanisms and Targeting Strategies in Cancer.